Shopping Cart
Remove All
Your shopping cart is currently empty
MJN228 is a lipid-binding protein nucleobindin-1 (NUCB1) inhibitor that blocks the AEA-DA probe labeling of endogenous NUCB1 in Neuro2a cells and can be used for the study of metabolic disorders.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $89 | In Stock | In Stock | |
| 5 mg | $219 | In Stock | In Stock | |
| 10 mg | $326 | - | In Stock | |
| 25 mg | $546 | - | In Stock | |
| 50 mg | $778 | - | In Stock |
| Description | MJN228 is a lipid-binding protein nucleobindin-1 (NUCB1) inhibitor that blocks the AEA-DA probe labeling of endogenous NUCB1 in Neuro2a cells and can be used for the study of metabolic disorders. |
| In vitro | 25 μM MJN228 significantly reduced lipid probe labeling of NUCB1 in Neuro2a cells. [1] MJN228 interfered with multiple intracellular lipid metabolic pathways. [1] |
| Synonyms | MJN-228, MJN 228 |
| Molecular Weight | 364.4 |
| Formula | C20H20N4O3 |
| Cas No. | 459168-97-9 |
| Smiles | O=C(N1CCN(CC1)C)C2=C(C3=CC=CC=C3)C4=C(C=CC([N+]([O-])=O)=C4)N2 |
| Relative Density. | 1.324 g/cm3 (Predicted) |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (54.88 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.